Source: |
Type: |
Enzymes involved in regulating gene expression by removing acetyl groups from histones, the proteins around which DNA is wrapped. -Many cancers exhibit altered expression levels of HDACs, which can contribute to the dysregulation of genes involved in cell growth, survival, and differentiation. -HDACs can repress the expression of tumor suppressor genes, leading to uncontrolled cell proliferation and survival. This repression can be a key factor in the development and progression of cancer. -HDAC inhibitors (HDACi) have been developed and are being investigated for their ability to reactivate silenced genes, induce cell cycle arrest, and promote apoptosis in cancer cells. -HDAC1, HDAC2): Often overexpressed in various cancers, including breast, prostate, and colorectal cancers. Their overexpression is associated with poor prognosis. -HDAC4, HDAC5): These may have both oncogenic and tumor-suppressive roles depending on the context and cancer type. -While HDACs are not classified as traditional oncogenes, their overexpression and activity can contribute to oncogenic processes. -HDAC inhibitor works by preventing the removal of acetyl groups from histones, thereby modulating gene expression, influencing cell behavior, and potentially reversing aberrant gene silencing seen in various diseases. -HDAC inhibitors can help reactivate these genes, thereby inhibiting growth and inducing apoptosis in cancer cells. |
2663- | AL, | Therapeutic Effect of Allicin on Glioblastoma |
- | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG |
3435- | aLinA, | Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines |
- | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | SiHa | - | in-vitro, | Cerv, | C33A |
1156- | And, | Exploring the potential of Andrographis paniculata for developing novel HDAC inhibitors: an in silico approach |
- | Analysis, | NA, | NA |
1151- | Api, | Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study |
- | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | 22Rv1 | - | in-vivo, | NA, | NA |
177- | Api, | Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21WAF1/CIP1 expression |
- | in-vitro, | BC, | MDA-MB-231 |
2664- | Api, | Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents |
- | Review, | Var, | NA |
2639- | Api, | Plant flavone apigenin: An emerging anticancer agent |
- | Review, | Var, | NA |
2631- | Api, | Apigenin Induces Autophagy and Cell Death by Targeting EZH2 under Hypoxia Conditions in Gastric Cancer Cells |
- | in-vivo, | GC, | NA | - | in-vitro, | GC, | AGS |
1547- | Api, | Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading |
- | Review, | NA, | NA |
1561- | Api, | Apigenin Reactivates Nrf2 Anti-oxidative Stress Signaling in Mouse Skin Epidermal JB6 P + Cells Through Epigenetics Modifications |
- | in-vivo, | Nor, | JB6 |
1433- | Ash, | SFN, | A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
3175- | Ash, | SFN, | Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
1080- | BA, | Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition |
- | in-vitro, | CRC, | HT-29 |
2047- | BA, | Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells |
- | in-vitro, | CRC, | T24 | - | in-vitro, | Nor, | SV-HUC-1 | - | in-vitro, | Bladder, | 5637 | - | in-vivo, | NA, | NA |
2050- | BA, | The Role of Sodium Phenylbutyrate in Modifying the Methylome of Breast Cancer Cells |
- | in-vitro, | BC, | MCF-7 |
2697- | BBR, | Structural exploration of common pharmacophore based berberine derivatives as novel histone deacetylase inhibitor targeting HDACs enzymes |
- | Analysis, | Var, | NA |
2698- | BBR, | A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine |
- | Analysis, | BC, | MDA-MB-231 |
2699- | BBR, | Plant Isoquinoline Alkaloid Berberine Exhibits Chromatin Remodeling by Modulation of Histone Deacetylase To Induce Growth Arrest and Apoptosis in the A549 Cell Line |
- | in-vitro, | Lung, | A549 |
2764- | BetA, | In silico profiling of histone deacetylase inhibitory activity of compounds isolated from Cajanus cajan |
- | Analysis, | Var, | NA |
3522- | Bor, | The Boron Advantage: The Evolution and Diversification of Boron’s Applications in Medicinal Chemistry |
- | Review, | Var, | NA |
3523- | Bor, | Design, Synthesis, and Biological Activity of Boronic Acid-Based Histone Deacetylase Inhibitors |
- | in-vitro, | Var, | NA |
696- | Bor, | Nothing Boring About Boron |
- | Review, | Var, | NA |
2794- | CHr, | An updated review on the versatile role of chrysin in neurological diseases: Chemistry, pharmacology, and drug delivery approaches |
- | Review, | Park, | NA | - | Review, | Stroke, | NA |
2798- | CHr, | Chrysin: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
2784- | CHr, | Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review) |
- | Review, | Var, | NA |
2785- | CHr, | Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin |
- | Review, | Var, | NA |
1505- | CUR, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
- | Review, | NA, | NA |
163- | CUR, | Epigenetic CpG Demethylation of the Promoter and Reactivation of the Expression of Neurog1 by Curcumin in Prostate LNCaP Cells |
- | in-vitro, | Pca, | LNCaP |
1863- | dietFMD, | Chemo, | Effect of fasting on cancer: A narrative review of scientific evidence |
- | Review, | Var, | NA |
672- | EGCG, | Molecular Targets of Epigallocatechin—Gallate (EGCG): A Special Focus on Signal Transduction and Cancer |
- | Review, | NA, | NA |
3201- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
- | Review, | NA, | NA |
3238- | EGCG, | Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications |
- | Review, | Var, | NA |
3229- | EGCG, | Epigallocatechin-3-gallate (EGCG) Alters Histone Acetylation and Methylation and Impacts Chromatin Architecture Profile in Human Endothelial Cells |
- | in-vitro, | Nor, | HMEC | - | in-vitro, | Nor, | HUVECs |
3230- | EGCG, | Green Tea Polyphenol Epigallocatechin 3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 116 Human Colon Cancer Cells |
- | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 |
3231- | EGCG, | Epigallocatechin-3-gallate restores mitochondrial homeostasis impairment by inhibiting HDAC1-mediated NRF1 histone deacetylation in cardiac hypertrophy |
- | in-vitro, | Nor, | NA |
3235- | EGCG, | (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells |
- | in-vivo, | Cerv, | HeLa |
3236- | EGCG, | BA, | Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate |
- | in-vitro, | Colon, | RKO | - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Colon, | HT29 |
3237- | EGCG, | (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression |
- | in-vivo, | AD, | NA |
1435- | GEN, | SFN, | The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
- | Review, | Var, | NA |
2868- | HNK, | Honokiol: A review of its pharmacological potential and therapeutic insights |
- | Review, | Var, | NA | - | Review, | Sepsis, | NA |
2875- | HNK, | Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | SCC, | H226 |
1064- | LT, | Cisplatin, | Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells |
- | vitro+vivo, | Lung, | LNM35 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
2915- | LT, | Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells |
- | in-vitro, | Colon, | HT29 | - | in-vitro, | CRC, | SNU-407 | - | in-vitro, | Nor, | FHC |
2919- | LT, | Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence |
- | Review, | Var, | NA |
2927- | LT, | Luteolin Causes 5′CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells |
- | in-vitro, | Cerv, | HeLa |
1196- | MAG, | 2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression |
- | in-vitro, | HCC, | NA |
2031- | PB, | Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model |
- | in-vivo, | AD, | NA |
2035- | PB, | Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinson’s Disease |
- | in-vitro, | Nor, | glial | - | in-vivo, | NA, | NA |
2049- | PB, | Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors |
- | Review, | Var, | NA |
2061- | PB, | Chemo, | Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells |
- | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | COLO357 | - | in-vitro, | PC, | Bxpc-3 |
2054- | PB, | Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axis |
- | in-vitro, | EC, | ISH | - | in-vitro, | EC, | HEC1B |
2052- | PB, | Lipid-regulating properties of butyric acid and 4-phenylbutyric acid: Molecular mechanisms and therapeutic applications |
- | Review, | NA, | NA |
2048- | PB, | Sodium Phenylbutyrate Inhibits Tumor Growth and the Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma In Vitro and In Vivo |
- | in-vitro, | OS, | CAL27 | - | in-vitro, | Oral, | HSC3 | - | in-vitro, | OS, | SCC4 | - | in-vivo, | NA, | NA |
2046- | PB, | Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | Nor, | MCF10 |
2045- | PB, | Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line |
- | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | LN-18 |
2043- | PB, | Cisplatin, | Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin |
- | in-vitro, | HNSCC, | UM-SCC-1 |
2042- | PB, | Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury |
- | in-vitro, | Nor, | NA |
2039- | PB, | TXNIP mediates the differential responses of A549 cells to sodium butyrate and sodium 4‐phenylbutyrate treatment |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 |
2029- | PB, | Phenylbutyric Acid: simple structure - multiple effects |
- | Review, | Var, | NA |
2030- | PB, | 4-Phenylbutyric acid protects against neuronal cell death by primarily acting as a chemical chaperone rather than histone deacetylase inhibitor |
- | Review, | Nor, | NA |
2074- | PB, | Chemo, | The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | Calu-6 | - | in-vitro, | Lung, | H1650 |
- | Trial, | CRC, | NA |
2067- | PB, | Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer |
- | in-vitro, | PC, | NA |
2064- | PB, | Rad, | Phenylbutyrate Attenuates the Expression of Bcl-XL, DNA-PK, Caveolin-1, and VEGF in Prostate Cancer Cells |
- | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
2026- | PB, | Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study |
- | Trial, | GBM, | NA |
2027- | PB, | Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors |
- | Trial, | Var, | NA |
2028- | PB, | Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms |
- | Review, | Var, | NA |
2077- | PB, | Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells |
- | in-vitro, | Liver, | HUH7 |
998- | PB, | Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect |
- | in-vivo, | NA, | NA |
1666- | PBG, | Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer |
- | Review, | Var, | NA |
1660- | PBG, | Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents |
- | Review, | Var, | NA |
1938- | PL, | Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation |
- | Study, | PSA, | NA | - | in-vivo, | NA, | NA |
3357- | QC, | The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes |
- | in-vitro, | AML, | HL-60 | - | NA, | NA, | U937 |
3359- | QC, | Quercetin modifies 5′CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells |
- | in-vitro, | Cerv, | HeLa |
3360- | QC, | Role of Flavonoids as Epigenetic Modulators in Cancer Prevention and Therapy |
- | Review, | Var, | NA |
3368- | QC, | The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update |
- | Review, | Var, | NA |
882- | RES, | Resveratrol: A Double-Edged Sword in Health Benefits |
- | Review, | NA, | NA |
883- | RES, | Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy |
1506- | RES, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
- | Review, | NA, | NA |
2040- | SAHA, | The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin |
- | in-vitro, | Pca, | LNCaP | - | in-vitro, | CRC, | T24 | - | in-vitro, | BC, | MCF-7 |
1062- | Sel, | Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells |
- | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | U87MG |
4198- | SFN, | Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways |
- | vitro+vivo, | AD, | NA |
3660- | SFN, | Sulforaphane - role in aging and neurodegeneration |
- | Review, | AD, | NA |
1722- | SFN, | Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems |
- | Review, | Var, | NA |
1725- | SFN, | Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway |
- | Review, | Var, | NA |
1730- | SFN, | Sulforaphane: An emergent anti-cancer stem cell agent |
- | Review, | Var, | NA |
1724- | SFN, | Sulforaphane: A review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials |
- | Review, | Var, | NA |
1494- | SFN, | doxoR, | Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model |
- | in-vivo, | BC, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
1484- | SFN, | Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action |
- | Review, | Var, | NA | - | Review, | AD, | NA |
1430- | SFN, | Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy |
- | Trial, | BC, | NA |
1428- | SFN, | Broccoli or Sulforaphane: Is It the Source or Dose That Matters? |
- | Review, | NA, | NA |
1454- | SFN, | Absorption and chemopreventive targets of sulforaphane in humans following consumption of broccoli sprouts or a myrosinase-treated broccoli sprout extract |
- | Human, | Nor, | NA |
1453- | SFN, | Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7 |
- | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
1452- | SFN, | Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells |
- | in-vitro, | GC, | AGS |
1434- | SFN, | GEM, | Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity |
- | in-vitro, | CCA, | HuCCT1 | - | in-vitro, | CCA, | HuH28 | - | in-vivo, | NA, | NA |
1496- | SFN, | VitD3, | Association between histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human colorectal cancer cells |
- | in-vitro, | CRC, | Caco-2 |
1497- | SFN, | Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells |
- | in-vitro, | Nor, | PrEC | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
1500- | SFN, | A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase |
- | in-vitro, | Nor, | HEK293 | - | in-vitro, | CRC, | HCT116 |
1502- | SFN, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
- | Review, | NA, | NA |
1437- | SFN, | Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition |
- | Review, | NA, | NA |
1458- | SFN, | Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma |
- | Review, | Bladder, | NA |
- | in-vitro, | Pca, | NA |
1508- | SFN, | Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment |
- | Review, | Var, | NA |
1507- | SFN, | Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects |
- | in-vivo, | Colon, | NA | - | Human, | Nor, | NA |
2554- | SFN, | Sulforaphane (SFN): An Isothiocyanate in a Cancer Chemoprevention Paradigm |
- | Review, | Var, | NA |
2555- | SFN, | Chemopreventive functions of sulforaphane: A potent inducer of antioxidant enzymes and apoptosis |
- | Review, | Var, | NA |
2556- | SFN, | The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review |
- | Review, | Var, | NA |
3192- | SFN, | Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention |
- | in-vitro, | Pca, | PC3 |
2448- | SFN, | Sulforaphane and bladder cancer: a potential novel antitumor compound |
- | Review, | Bladder, | NA |
1061- | SFN, | Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors |
- | vitro+vivo, | NA, | NA |
3282- | SIL, | Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions |
- | Review, | NA, | NA |
3288- | SIL, | Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations |
- | Review, | Var, | NA |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
3421- | TQ, | Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer |
- | Analysis, | Nor, | NA | - | in-vivo, | Nor, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HaCaT |
3426- | TQ, | Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms |
- | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | AML, | JK |
3425- | TQ, | Advances in research on the relationship between thymoquinone and pancreatic cancer |
3423- | TQ, | Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics |
- | Review, | Var, | NA |
3422- | TQ, | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
- | Review, | Var, | NA |
3407- | TQ, | Thymoquinone and its pharmacological perspective: A review |
- | Review, | NA, | NA |
2119- | TQ, | Dual properties of Nigella Sativa: anti-oxidant and pro-oxidant |
- | Review, | Var, | NA |
2103- | TQ, | Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells |
- | in-vitro, | PC, | Hs766t | - | in-vitro, | PC, | MIA PaCa-2 |
2102- | TQ, | A review on therapeutic potential of Nigella sativa: A miracle herb |
- | Review, | Var, | NA |
2101- | TQ, | HDAC inhibition by Nigella sativa L. sprouts extract in hepatocellular carcinoma: an approach to study anti-cancer potential |
- | Study, | HCC, | NA |
2100- | TQ, | Dual properties of Nigella Sative: Anti-oxidant and Pro-oxidant |
- | Review, | NA, | NA |
2105- | TQ, | Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation |
- | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | Hs766t | - | in-vivo, | NA, | NA |
2108- | TQ, | Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa |
- | Review, | Var, | NA |
2353- | TQ, | The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies |
- | Review, | PC, | NA |
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:140 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid